Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.
about
Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future.Purinergic regulation of duodenal surface pH and ATP concentration: implications for mucosal defence, lipid uptake and cystic fibrosisCapturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.Natural Compounds as Therapeutic Agents in the Treatment Cystic FibrosisHuman neutrophil peptides and phagocytic deficiency in bronchiectatic lungs.Update on antibiotics for infection control in cystic fibrosis.Purinergic signalling in epithelial ion transport: regulation of secretion and absorption.Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.Update on key emerging challenges in cystic fibrosis.ENaC inhibitors for the treatment of cystic fibrosis.Epithelial Na+ channel inhibitors for the treatment of cystic fibrosis.Extracellular alkalinization stimulates calcium-activated chloride conductance in cystic fibrosis human airway epithelial cells.Phospholipase C-β3 is a key modulator of IL-8 expression in cystic fibrosis bronchial epithelial cells.Primary bronchial epithelial cell culture from explanted cystic fibrosis lungs.Basic research funding by philanthropic organizations: a case in point.Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
P2860
Q33771660-C89D97F5-ADA6-42E8-B30B-1958EC19C124Q34335468-04CD2BF9-82A0-461B-B727-93BEEBAA6677Q36354702-2A11C230-B4BC-463A-989B-4E624CDE4F1DQ36790589-44023931-DCD1-4CE5-BD82-F925A6174778Q37272618-1AE7CAAC-F23E-49AB-A8D2-EF9280577754Q37608274-D5C8413C-DEF7-4A8B-B116-388A454BBB9AQ37809120-1383FE0F-8052-4C5C-8953-E6645CA65545Q37849777-74F4573B-ED3D-4AF1-BF2C-101B202A09EDQ38179169-7238A7D7-FF9B-4D73-A2C3-3F0248AF5FA3Q38309753-E4458456-D7B7-4895-AC23-EA680F15DD4EQ39428158-0AFCE649-E7CC-43AE-9A37-A9DF30576C59Q39562897-18DA554C-976A-4207-9148-84D4E2F5D899Q39575146-A90D88FD-0513-46EC-AA84-354FA9B40630Q43141760-578C3614-382C-41A5-A21B-487F16AAFA19Q54513992-3DAE2326-65DB-47A4-8127-17FD0495CD53Q58914917-6D351663-F078-4917-B1A4-47EECCAA0932
P2860
Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@en
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@nl
type
label
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@en
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@nl
prefLabel
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@en
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@nl
P2860
P1476
Front-runners for pharmacother ...... ort defect in cystic fibrosis.
@en
P2093
Mark T Clunes
Richard C Boucher
P2860
P304
P356
10.1016/J.COPH.2008.04.006
P577
2008-05-28T00:00:00Z